A phase I/II first-in-human study of a novel anti-MAGE-A4 TCR/anti-CD3 bispecific (IMC-C103C) as monotherapy and in combination with atezolizumab in HLA-A(star)02:01-positive patients with MAGE-A4-positive advanced solid tumors (IMC-C103C-101).-MedSci.cn

A phase I/II first-in-human study of a novel anti-MAGE-A4 TCR/anti-CD3 bispecific (IMC-C103C) as monotherapy and in combination with atezolizumab in HLA-A(star)02:01-positive patients with MAGE-A4-positive advanced solid tumors (IMC-C103C-101).

Blumenschein, GR; Davar, D; Gutierrez, R; Segal, NH; Johnson, ML; Dar, MM; Marshall, S

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (15):

科室
- - 订阅+
  - 更多科室
工具
服务